Ventyx ‘unequivocally impressive data’ should spur Sanofi, says Clear Street

Clear Street analyst Kaveri Pohlman notes Ventyx (VTYX) shares jumped about 85% after hours following the company’s report of “unequivocally impressive data” from its brain-penetrant oral NLRP3 inhibitor, VTX3232, an asset on which Sanofi (SNY) holds the right of first negotiation. The firm, which “strongly” believes that the “robust, clean data” should “prompt Sanofi to act decisively,” has a Buy rating and $11 price target on Ventyx shares.